Prestige Consumer Healthcare/$PBH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Prestige Consumer Healthcare

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Ticker

$PBH
Sector

Primary listing

NYSE

Employees

600

PBH Metrics

BasicAdvanced
$3.3B
15.67
$4.26
0.44
-

What the Analysts think about PBH

Analyst ratings (Buy, Hold, Sell) for Prestige Consumer Healthcare stock.

Bulls say / Bears say

The deal to acquire Pillar5 Pharma brings sterile manufacturing in-house for Clear Eyes, removing key third-party supply obstacles and positioning PBH to expand production capacity in the second half of FY2026. (Reuters)
International OTC segment revenues increased 6.1% year-over-year in Q1 FY2026, demonstrating the company’s effective geographic diversification and giving it a hedge against North American supply disruptions. (Nasdaq)
While revenue declined 6.6%, Q1 diluted EPS rose 6% to $0.95, driven by strong margin gains and disciplined cost management across the business. (Reuters)
Q1 FY2026 revenues dropped 6.6% to $249.5 million, mainly due to ongoing Clear Eyes supply shortages, exposing the company's vulnerability to heavy reliance on a single product line. (Reuters)
The company revised its full-year fiscal 2026 revenue outlook downward to $1.100 billion–$1.115 billion from $1.140 billion–$1.155 billion, indicating slower growth prospects than previously expected. (Reuters)
At the end of Q1, PBH had net long-term debt of $992.7 million compared to $139.5 million in cash and equivalents, leaving it with net debt above $850 million, which could limit its financial flexibility. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.

PBH Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PBH Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PBH

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs